[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100396071":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":56,"centralContacts":60,"locations":70,"responsibleParty":90,"collaborators":64,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":64,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":64,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":73,"whyStopped":64,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"DNF-N","EXPERIMENTAL","1. Induction chemotherapy:\n\n   three cycles of intravenous docetaxel 60 mg\u002Fm² on day 1, intravenous nedaplatin 60 mg\u002Fm² on day 1, and continuous intravenous fluorouracil 600 mg\u002Fm² per day from day 1 to day 5, every 3 weeks\n2. Concurrent chemoradiotherapy:\n\n   three cycles of 100 mg\u002Fm² nedaplatin every 3 weeks, concurrently with intensity-modulated radiotherapy\n3. Radiotherapy: radical intense modulated radiation therapy",[13,14,15],"Drug: Docetaxel, nedaplatin, fluorouracil","Drug: Nedaplatin","Radiation: Intensity modulated-radiotherapy",{"label":17,"type":18,"description":19,"interventionNames":20},"DPF-P","ACTIVE_COMPARATOR","1. Induction chemotherapy:\n\n   three cycles of intravenous docetaxel 60 mg\u002Fm² on day 1, intravenous cisplatin 60 mg\u002Fm² on day 1, and continuous intravenous fluorouracil 600 mg\u002Fm² per day from day 1 to day 5, every 3 weeks\n2. Concurrent chemoradiotherapy:\n\n   three cycles of 100 mg\u002Fm² cisplatin every 3 weeks, concurrently with intensity-modulated radiotherapy\n3. Radiotherapy: radical intense modulated radiation therapy",[21,22,15],"Drug: Docetaxel, cisplatin, fluorouracil","Drug: Cisplatin",[24,31,37,43,49],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Docetaxel, nedaplatin, fluorouracil","Induction chemotherapy. Docetaxel 60 mg\u002Fm2 intravenous day1. Nedaplatin 60 mg\u002Fm2 intravenous day1. Fluorouracil 3000 mg\u002Fm2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.",[9],[30],"DNF",{"type":25,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Docetaxel, cisplatin, fluorouracil","Induction chemotherapy. Docetaxel 60 mg\u002Fm2 intravenous day1. Cisplatin 60 mg\u002Fm2 intravenous day1. Fluorouracil 3000 mg\u002Fm2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.",[17],[36],"DPF",{"type":25,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Nedaplatin","Concurrent chemotherapy. Nedaplatin 100 mg\u002Fm2 intravenous at day1, 22, 43 of radiotherapy.",[9],[42],"NDP",{"type":25,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"Cisplatin","Concurrent chemotherapy. Cisplatin 100 mg\u002Fm2 intravenous at day1, 22, 43 of radiotherapy.",[17],[48],"DDP",{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"RADIATION","Intensity modulated-radiotherapy","Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.",[9,17],[55],"IMRT",[57],{"name":58,"affiliation":5,"role":59},"Jinquan Liu, M.D","STUDY_DIRECTOR",[61,66],{"name":58,"role":62,"phone":63,"phoneExt":64,"email":65},"CONTACT","0086-137-1086-6485",null,"609149209@qq.com",{"name":67,"role":62,"phone":68,"phoneExt":64,"email":69},"Bin Qi, M.D","0086-135-8058-0985","qibin020@126.com",[71],{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"Department of radiotherapy(Section 5),Affiliated Cancer Hospital & Institute of Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","510095","China","CN",{"type":80,"coordinates":81},"Point",[82,83],113.25,23.11667,{"lat":83,"lon":82},[86,87,88],{"name":58,"role":62,"phone":63,"phoneExt":64,"email":65},{"name":67,"role":62,"phone":68,"phoneExt":64,"email":69},{"name":58,"role":89,"phone":64,"phoneExt":64,"email":64},"PRINCIPAL_INVESTIGATOR",{"type":89,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":64,"oldOrganization":64},"Jin-Quan Liu","President of Affiliated Tumor Hospital of Guangzhou Medical University","100396071","phase-3-nedaplatin-versus-cisplatin-in-treatment-for-nasopharyngeal-carcinoma-100396071",false,"NCT04437329","Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma","Nedaplatin Versus Cisplatin in Induction Chemotherapy Combined With Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma：a Prospective, Parallel, Randomized, Open Labeled, Phase III Non-Inferiority Clinical Study","Inclusion Criteria:\n\n1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III\n2. Original clinical staged as III-IVa (except T3-4N0) according to the 8th edition American Joint Committee on Cancer staging system\n3. No evidence of distant metastasis (M0)\n4. Age between 18-65\n5. WBC≥4×10\\^9\u002F l, platelet ≥ 100×10\\^9\u002F l and hemoglobin ≥ 90g\u002Fl\n6. With normal liver function test (TBIL、ALT、AST ≤ 2.5×uln)\n7. With normal renal function test (creatinine ≤ 1.5×uln or ccr ≥ 60ml\u002Fmin)\n8. Satisfactory performance status: KARNOFSKY scale (KPS) \\> 70\n9. Patients must give signed informed consent\n\nExclusion Criteria:\n\n1. Histologically confirmed keratinizing nasopharyngeal carcinoma (WHO I)\n2. Age \\>65 or \\\u003C 18 years\n3. Treatment with palliative intent\n4. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer\n5. History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes\n6. History of previous radiotherapy\n7. Pregnancy or lactation\n8. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, acute exacerbation of chronic obstructive pulmonary disease or other respiratory illness requiring admission to hospital, active hepatitis, and mental disturbance","ALL","18 Years","65 Years",{"count":104,"type":105},352,"ESTIMATED","INTERVENTIONAL",[108],"PHASE3","To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.",[111],"Nasopharyngeal Carcinoma",[113,114,115,116],"induction chemotherapy","nedaplatin","cisplatin","concurrent chemoradiotherapy","2022-05-06",{"date":119,"type":120},"2022-05-10","ACTUAL",{"date":122,"type":120},"2020-08-01",{"date":124,"type":105},"2029-06-30",{"name":5,"class":6},1]